cells/l not explained by other clinical disorders. Predominance of small, morphologically mature lymphocytes in the blood smear. Immunophenotyping: the composite immunophenotype CD5+, CD19+, CD20+ (low), CD23+, sIg low, CD79b low, FMC7-allows the distinction of most cases of B-cell type CLL from other CD5+ B-cell lymphoma. Bone marrow biopsy is not needed for diagnosis, but is recommended before initiating therapy, in order to evaluate unclear cytopenia.
The following additional examinations are recommended for the initial evaluation [V, D]:
Physical examination including a careful palpation of all lymph node areas. LDH, bilirubin, serum protein electrophoresis, Coombs test.
Chest X-ray. Because the detection of cytogenetic abnormalities by fluorescent in situ hybridization (FISH) has apparent prognostic value, this examination should be carried out during the initial evaluation of a patient with CLL. For prognostic and therapeutic reasons, every effort should be made for adequate differential diagnosis against mantle zone lymphoma using morphology, immunophenotyping and FISH and/or molecular biology for detection of (t11;14) translocation and staining for cyclin D1. Newer prognostic parameters such as the expression of CD38, ZAP70 and the immunoglobulin mutational status (IgVH mutation) may predict the time to progression from an early stage to advanced disease, but should not be used for a treatment indication in CLL. At present, their value should be further investigated in clinical trials.
staging and risk assessment
The median survival at diagnosis varies between 1 and >10 years according to the initial stage of the disease. Two clinical staging systems are used. In Europe, the Binet staging system is generally more accepted. It separates three groups of different prognosis ( Table 1) .
treatment of early disease
Binet stage A and B without symptoms; Rai 0, I and II without symptoms. In physically fit patients (physically active, no major health problems) the combination of fludarabine and cyclophosphamide (FC) is currently recommended as initial treatment, because this combination induces a higher rate of complete remission and longer progression-and treatment-free survival than chlorambucil or purine analog monotherapy [I, A]. The combination of cladribine plus cyclophosphamide has not produced significantly longer progression-free survival (PFS) than cladribine alone. The addition of monoclonal antibodies such as rituximab (R) or alemtuzumab (A) to purine analog-based treatment regimens results in very high and qualitatively better remission, but a benefit in PFS is currently being tested in randomized trials [III, B] .
In patients with relevant co-morbidity (in particular renal insufficiency) chlorambucil or a dose-reduced fludarabine monotherapy can be given as first-line therapy, because they appear to be less myelotoxic than the FC combination.
Patients showing the chromosomal defect del(17p) frequently do not respond to conventional chemotherapy with fludarabine or FC. These patients may be initially treated with alemtuzumab monotherapy or combination therapy. Allogeneic transplantation within clinical trials might be considered as first-line therapy in these patients. 
second-line chemotherapy

follow-up
Follow up of asymptomatic patients should include a blood cell count every three months, as well as a regular examinations of lymph nodes, liver and spleen. Special attention should be paid to the appearance of autoimmune cytopenias (autoimmune hemolytic anemia, autoimmune thrombocytopenia) that occur in 10-15% of CLL patients [V, D] . 
